Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer.

Pierfranco Conte,Valentina Guarneri,Daniele Generali,Alberto Bottini,Letizia Bazzola,Federico Piacentini,F. Artioli,Katia Cagossi,G. Bisagni,M. Bagnalasta,Enrico Tagliafico,Elena Barbieri,Luigi Cavanna,Alberto Ravaioli,Roberto D’Amico,Roberto Vicini,Antonio Frassoldati

Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer.

2011

Pierfranco Conte
Valentina Guarneri
Daniele Generali
Alberto Bottini
Letizia Bazzola
Federico Piacentini
F. Artioli
Katia Cagossi
G. Bisagni
M. Bagnalasta
Enrico Tagliafico
Elena Barbieri
Luigi Cavanna
Alberto Ravaioli
Roberto D’Amico
Roberto Vicini
Antonio Frassoldati

550 Background: The crosstalk between the ER pathway and erbB receptor family is emerging as a mechanism of resistance to hormonal therapy. The combination of lapatinib-letrozole might prevent or d...

Keywords:

Breast cancer
Placebo
Hormone receptor
Neoadjuvant Study
HER2 negative
Oncology
Lapatinib
Letrozole
Internal medicine
Medicine
double blind
Hormonal therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations